News Category
Onco-Innovations has moved its lead PNKP inhibitor ONC010 closer to human trials by achieving high-purity API production and establishing a regulatory...
BioVersys, a clinical-stage biopharmaceutical company developing novel antibacterials for multi-drug resistant infections, will present at the H.C. Wa...
The launch of SEAM@InnoHK marks a significant step in Hong Kong's innovation landscape, focusing on sustainable development, energy, advanced manufact...
NanoViricides is moving its measles drug candidate NV-387 into Phase II trials, leveraging FDA designations that could expedite development and offer ...
TransCode Therapeutics' lead candidate TTX-MC138 showed significant survival benefits and reduced miR-10b expression in a preclinical breast cancer bo...
Oragenics reports progress in its Phase IIa concussion trial and addresses FDA feedback and NYSE American listing compliance, highlighting key milesto...
Creative Biolabs updates its in vivo CAR-T development services, offering both viral and non-viral approaches to support researchers exploring direct ...
Lonza appoints Samanta Cimitan as its first Chief Commercial Officer, a move that strengthens its customer-centric approach and unified go-to-market s...
The NMPA approval allows Heidelberg Pharma and Huadong Medicine to advance HDP-101 combination therapy for multiple myeloma, expanding its potential a...
A peer-reviewed study in Critical Care Medicine validates VolitionRx's Nu.Q NETs H3.1 biomarker as an independent predictor of mortality and renal rep...
Monod Bio's licensing agreement with SignalChem Biotech expands access to AI-designed proteins for custom assays, advancing drug discovery efficiency.
GeoVax Labs announced a warrant inducement transaction with an existing institutional investor, generating approximately $3.6 million in gross proceed...
Lakewood-Amedex Biotherapeutics is now a B2i Digital Featured Company as it prepares a Phase 2a trial for Nu-3, a novel antimicrobial gel targeting in...
Citius Pharmaceuticals' commercial launch of LYMPHIR and its late-stage pipeline, including Mino-Lok and Halo-Lido, position the company to address si...
Annovis Bio's upcoming webinar highlights its pivotal Phase 3 Alzheimer's trial and expansion into Parkinson's disease, signaling progress in neurodeg...
A new study suggests that a personalized mRNA vaccine derived from a patient's tumor tissue may prevent melanoma recurrence for years, highlighting th...
Creative Biolabs announces an expert webinar on modeling T cell dysfunction in the tumor microenvironment, highlighting the importance of advanced pre...
Synthesis Peptides now provides third-party Certificates of Analysis for all 40+ research peptides, enhancing transparency and reliability for scienti...
A novel T cell therapy may provide a new treatment avenue for recurrent glioblastoma, a condition with limited options, highlighting the importance of...
VERAXA Biotech and Secarna Pharmaceuticals announced initial positive results from their collaboration to develop AOCs for autoimmune diseases, showin...
VERAXA Biotech's VXA-222 bispecific ADC program moves to preclinical validation, highlighting the company's progress in oncology and its expanding IP ...
Scinai Immunotherapeutics' first-half 2026 results show revenue growth and a significant bargain purchase gain, while the company progresses its expan...
A new composite scoring system, the Seven Up score, identifies that most early liver rejection episodes resolve without treatment, potentially reducin...
VERAXA Biotech's favorable Scientific Advice from Germany's Paul-Ehrlich-Institute validates its lead BiTAC-TCE cancer therapy's development strategy,...
VERAXA Biotech's proprietary BiTAC platform and recent pipeline progress, including VXA-222 and its lead T-cell engager, underscore its potential to i...
Onco-Innovations has entered into a letter of intent to acquire an exclusive option on Ifowonco's oral small-molecule LAG-3 inhibitor program, potenti...
Creative Biolabs has expanded its complement assay services, offering advanced tools like C3b deposition and hemolytic inhibition assays to support pr...
Quantum BioPharma's Lucid-MS targets myelin preservation rather than immune suppression, offering a potential new approach to treating multiple sclero...
Silo Pharma's receipt of a Canadian patent allowance for its lead asset SPC-15 strengthens its intellectual property position and advances its PTSD tr...
Quantum BioPharma's FDA-cleared phase 2 trial of Lucid-MS highlights a shift in MS treatment toward myelin protection, addressing the unmet need of pr...
Regentis Biomaterials received a Japanese Notice of Allowance for its GelrinC manufacturing process, expanding its global IP portfolio to nearly 30 pa...
VERAXA Biotech's collaboration with Ardigen aims to use AI to enhance its oncology pipeline, potentially reviving abandoned drug targets and improving...
VERAXA Biotech's collaboration with Ardigen uses AI to optimize its oncology pipeline, potentially reducing development risks and reviving abandoned t...
Nanox Imaging's subsidiary has entered an exclusive UK reseller agreement for its AI bone solution HealthOST, following a NICE recommendation, aiming ...
Helix BioPharma's appointment of a seasoned oncology executive signals a strategic shift towards advancing its lead candidate L-DOS47 and preparing LE...
Quantum BioPharma's significant cost reductions and FDA approval for its Phase 2 trial of Lucid-MS signal a strategic push to develop a treatment for ...
Regentis Biomaterials is progressing its GelrinC cartilage repair implant through a pivotal U.S. trial while simultaneously scaling manufacturing and ...
Helix Biopharma's board reshuffle, including the resignation of Janusz Grabski and the appointment of CEO Thomas Mehrling, reflects a strategic move t...
Onco-Innovations is progressing its precision oncology pipeline by advancing ONC010, a nanoparticle-encapsulated PNKP inhibitor, through critical manu...
Researchers at the University of Manchester discovered that a subset of immune cells, often overlooked, is vital for initiating and sustaining the imm...
Quantum BioPharma reports significant expense reductions and FDA approval for its Phase 2 trial of Lucid-MS in progressive multiple sclerosis, strengt...
Regentis Biomaterials is accelerating GelrinC's path to market by simultaneously advancing US pivotal trials and European commercialization, potential...
HeartBeam's Q2 2026 results show significant progress in its heart attack detection program and commercial launch, with cash runway extended into 2027...
Lantern Pharma's Q2 2026 results highlight progress in its AI-driven oncology pipeline and the establishment of Open Medicine AI as a separate company...
NeOnc Technologies' lead candidate NEO100 met its primary endpoint in a Phase 2a trial for recurrent brain cancer, with median overall survival of 26....
Quantum BioPharma's focus on progression independent of relapse activity (PIRA) and chronic active lesions in MS development signals a shift toward ad...
GeoVax offers its MVA-based hemorrhagic fever vaccine candidates and expertise to support the response to the escalating Ebola outbreak in Congo, whil...
Nutriband's CEO will present at the 2026 Georgia Life Sciences Summit, underscoring the company's innovative AVERSA technology aimed at preventing opi...
